{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T08:18:25Z","timestamp":1773908305869,"version":"3.50.1"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2020,11,20]],"date-time":"2020-11-20T00:00:00Z","timestamp":1605830400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Novartis Pharmaceuticals"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,5,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>BACKGROUND<\/jats:title>\n                  <jats:p>The 2017 hypertension guidelines lowered systolic blood pressure (BP) goals to &amp;lt;130 mm Hg and redefined resistant hypertension. We investigated if these changes alter the cardiovascular benefits demonstrated by combining a calcium channel blocker (CCB), rather than hydrochlorothiazide (HCTZ), with an angiotensin-converting enzyme inhibitor (ACEI).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>METHODS<\/jats:title>\n                  <jats:p>In this post hoc analysis of the Avoiding Cardiovascular Events Through Combination Therapy in Patients Living with Systolic Hypertension trial (n = 11,506), we compared the primary composite outcome (cardiovascular death, myocardial infarction, stroke, hospitalization for angina, resuscitation after sudden cardiac death, and coronary revascularization) between the 2 combination-treatment limbs in patients achieving a systolic BP \u2264130 mm Hg and those with \u201capparent resistant hypertension\u201d (prescribed \u22654 antihypertensive medications).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>Among study patients, 5,221 (45.4%) achieved a systolic BP \u2264130 mm Hg. There were fewer primary endpoints in the amlodipine\/benazepril (9.2%) vs. the HCTZ\/benazepril (10.9%) limb (adjusted hazard ratio [HR] 0.83, 95% confidence interval [CI], 0.70\u20130.99). There were also fewer primary endpoints in the amlodipine\/benazepril (12.8%) vs. the HCTZ\/benazepril (15.2%) limb (n = 4,451, 38.7%) among patients with apparent resistant hypertension (HR 0.81, 95% CI, 0.70\u20130.95).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>Combination therapy adding a CCB, rather than HCTZ, to an ACEI was more effective in preventing composite cardiovascular events even in hypertensive patients achieving aggressive systolic BP targets as well as in those with apparent resistant hypertension. Our findings add support that most patients, including those following contemporary clinical guidelines, will benefit from this combination.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CLINICAL TRIALS REGISTRATION<\/jats:title>\n                  <jats:p>Trial Number NCT00170950.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ajh\/hpaa192","type":"journal-article","created":{"date-parts":[[2020,11,17]],"date-time":"2020-11-17T20:08:42Z","timestamp":1605643722000},"page":"531-539","source":"Crossref","is-referenced-by-count":3,"title":["Cardiovascular Benefits of Angiotensin-Converting Enzyme Inhibition Plus Calcium Channel Blockade in Patients Achieving Tight Blood Pressure Control and With Resistant Hypertension"],"prefix":"10.1093","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8521-7262","authenticated-orcid":false,"given":"Robert D","family":"Brook","sequence":"first","affiliation":[{"name":"Division of Cardiovascular Medicine, University of Michigan , Ann Arbor, Michigan, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niko","family":"Kaciroti","sequence":"additional","affiliation":[{"name":"Center for Human Growth and Development and Department of Biostatistics, University of Michigan , Ann Arbor, Michigan, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Bakris","sequence":"additional","affiliation":[{"name":"The University of Chicago Medicine , Chicago, Illinois, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bj\u00f6rn","family":"Dahl\u00f6f","sequence":"additional","affiliation":[{"name":"Sahlgrenska University Hospital \u00d6stra , G\u00f6thenburg, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bertrtam","family":"Pitt","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, University of Michigan , Ann Arbor, Michigan, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Velazquez","sequence":"additional","affiliation":[{"name":"Duke University School of Medicine , Durham, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael A","family":"Weber","sequence":"additional","affiliation":[{"name":"State University of New York Downstate , Brooklyn, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth A","family":"Jamerson","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, University of Michigan , Ann Arbor, Michigan, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,11,20]]},"reference":[{"key":"2022101009224426600_CIT0001","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa0806182","article-title":"Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients","volume":"359","author":"Jamerson","year":"2008","journal-title":"N Engl J Med"},{"key":"2022101009224426600_CIT0002","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.amjcard.2013.03.026","article-title":"Comparison of benazepril plus amlodipine or hydrochlorothiazide in high-risk patients with hypertension and coronary artery disease","volume":"112","author":"Bakris","year":"2013","journal-title":"Am J Cardiol"},{"key":"2022101009224426600_CIT0003","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jacc.2010.02.046","article-title":"Cardiovascular events during differing hypertension therapies in patients with diabetes","volume":"56","author":"Weber","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"2022101009224426600_CIT0004","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/S0140-6736(09)62100-0","article-title":"Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial","volume":"375","author":"Bakris","year":"2010","journal-title":"Lancet"},{"key":"2022101009224426600_CIT0005","doi-asserted-by":"crossref","first-page":"e006940","DOI":"10.1161\/JAHA.117.006940","article-title":"Prior medications and the cardiovascular benefits from combination angiotensin converting enzyme inhibition plus calcium channel blockade among high-risk hypertensive patients","volume":"7","author":"Brook","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"2022101009224426600_CIT0006","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1056\/NEJMc1001410","article-title":"24-Hour ambulatory blood pressure in the ACCOMPLISH trial","volume":"363","author":"Jamerson","year":"2010","journal-title":"N Engl J Med"},{"key":"2022101009224426600_CIT0007","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jash.2011.01.002","article-title":"Initial hypertension treatment: one combination fits most?","volume":"5","author":"Brook","year":"2011","journal-title":"J Am Soc Hypertens"},{"key":"2022101009224426600_CIT0008","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1161\/HYP.0000000000000066","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"71","author":"Whelton","year":"2018","journal-title":"Hypertension"},{"key":"2022101009224426600_CIT0009","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jash.2010.02.005","article-title":"Combination therapy in hypertension","volume":"4","author":"Gradman","year":"2010","journal-title":"J Am Soc Hypertens"},{"key":"2022101009224426600_CIT0010","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1161\/CIRCRESAHA.118.313294","article-title":"Two-drug combinations as first-step antihypertensive treatment","volume":"124","author":"Mancia","year":"2019","journal-title":"Circ Res"},{"key":"2022101009224426600_CIT0011","doi-asserted-by":"crossref","first-page":"212531","DOI":"10.7573\/dic.212531","article-title":"Combination therapy in the treatment of hypertension","volume":"7","author":"Guerrero-Garc\u00eda","year":"2018","journal-title":"Drugs Context"},{"key":"2022101009224426600_CIT0012","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1161\/HYP.0000000000000084","article-title":"Resistant hypertension: detection, evaluation, and management: a scientific statement from the American Heart Association","volume":"72","author":"Carey","year":"2018","journal-title":"Hypertension"},{"key":"2022101009224426600_CIT0013","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1161\/HYPERTENSIONAHA.112.194167","article-title":"Initial monotherapy and combination therapy and hypertension control the first year","volume":"59","author":"Egan","year":"2012","journal-title":"Hypertension"},{"key":"2022101009224426600_CIT0014","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1161\/HYPERTENSIONAHA.112.201566","article-title":"Initial combination therapy reduces the risk of cardiovascular events in hypertensive patients: a matched cohort study","volume":"61","author":"Gradman","year":"2013","journal-title":"Hypertension"},{"key":"2022101009224426600_CIT0015","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1111\/jch.12771","article-title":"Angiotensin system blockade combined with calcium channel blockers is superior to other combinations in cardiovascular protection with similar blood pressure reduction: a meta-analysis in 20,451 hypertensive patients","volume":"18","author":"Chi","year":"2016","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"2022101009224426600_CIT0016","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1007\/s11255-018-1991-x","article-title":"The benefits of angiotensin-converting enzyme inhibitors\/angiotensin II receptor blockers combined with calcium channel blockers on metabolic, renal, and cardiovascular outcomes in hypertensive patients: a meta-analysis","volume":"50","author":"Pongpanich","year":"2018","journal-title":"Int Urol Nephrol"},{"key":"2022101009224426600_CIT0017","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/j.1751-7176.2011.00512.x","article-title":"Thiazide and loop diuretics","volume":"13","author":"Sica","year":"2011","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"2022101009224426600_CIT0018","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1161\/CIRCULATIONAHA.110.983874","article-title":"Meta-analysis: impact of drug class on adherence to antihypertensives","volume":"123","author":"Kronish","year":"2011","journal-title":"Circulation"},{"key":"2022101009224426600_CIT0019","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1056\/NEJMoa1901113","article-title":"Comparison of dual therapies for lowering blood pressure in black Africans","volume":"380","author":"Ojji","year":"2019","journal-title":"N Engl J Med"},{"key":"2022101009224426600_CIT0020","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","article-title":"2018 ESC\/ESH Guidelines for the management of arterial hypertension","volume":"39","author":"Williams","year":"2018","journal-title":"Eur Heart J"},{"key":"2022101009224426600_CIT0021","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1161\/HYPERTENSIONAHA.118.12156","article-title":"Intensive blood pressure treatment for resistant hypertension. Secondary analysis of a randomized controlled trial","volume":"73","author":"Tsujimoto","year":"2019","journal-title":"Hypertension"}],"container-title":["American Journal of Hypertension"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajh\/advance-article-pdf\/doi\/10.1093\/ajh\/hpaa192\/36639518\/hpaa192.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajh\/article-pdf\/34\/5\/531\/46403262\/hpaa192.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajh\/article-pdf\/34\/5\/531\/46403262\/hpaa192.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T09:23:10Z","timestamp":1665393790000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajh\/article\/34\/5\/531\/5996073"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,20]]},"references-count":21,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020,11,20]]},"published-print":{"date-parts":[[2021,5,22]]}},"URL":"https:\/\/doi.org\/10.1093\/ajh\/hpaa192","relation":{},"ISSN":["0895-7061","1941-7225"],"issn-type":[{"value":"0895-7061","type":"print"},{"value":"1941-7225","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,5,1]]},"published":{"date-parts":[[2020,11,20]]}}}